Obatoclax Mesylate in Samples From Young Patients With Acute Myeloid Leukemia
RATIONALE: Studying the effects of obatoclax mesylate in cell samples from patients with cancer in the laboratory may help doctors learn more about the effects of obatoclax mesylate on cancer cells. It may also help doctors identify biomarkers related to cancer.
PURPOSE: This research study is studying obatoclax mesylate in samples from young patients with acute myeloid leukemia.
Genetic: gene expression analysis
Genetic: microarray analysis
Genetic: protein expression analysis
Genetic: reverse transcriptase-polymerase chain reaction
Genetic: western blotting
Other: laboratory biomarker analysis
Other: pharmacological study
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||SCOR in Targeted Therapies for Infant Leukemias Project 2: Targeting Apoptosis in Leukemia in Infants|
- Obatoclax mesylate activity [ Designated as safety issue: No ]
- Optimum in vitro combinations of obatoclax mesylate [ Designated as safety issue: No ]
- Pharmacodynamic (PD) biomarkers of activity [ Designated as safety issue: No ]
- Cell death mechanism in multiple-lineage leukemia (MLL) acute myeloid leukemia (AML) [ Designated as safety issue: No ]
- Disease progression in a xenograft model of MLL-rearranged infant AML [ Designated as safety issue: No ]
- Physical assessment (in xenograft model) [ Designated as safety issue: No ]
- Peripheral blast count reduction [ Designated as safety issue: No ]
- Apoptosis and/or ATG induction [ Designated as safety issue: No ]
- Modulation of relevant PD biomarkers [ Designated as safety issue: No ]
|Study Start Date:||June 2010|
|Primary Completion Date:||May 2016 (Final data collection date for primary outcome measure)|
- Determine comprehensive gene and protein expression profiles of in vitro sensitivity and resistance to obatoclax mesylate in multiple-lineage leukemia (MLL)-rearranged cell lines and primary infant acute myeloid leukemia (AML) samples.
- Define optimum in vitro combinations of obatoclax mesylate targeting pro-survival BCL-2 family proteins with cytotoxic drugs in MLL-rearranged leukemia cell lines and primary infant AML samples.
- Identify synergistic combinations based on a pharmacodynamic modeling and simulation construct.
- Determine whether combinations of obatoclax mesylate targeting pro-survival BCL-2 family proteins with cytotoxic drugs improves survival in a xenograft model of MLL-rearranged infant AML.
OUTLINE: This is a multicenter study.
Obatoclax mesylate activity is assessed via the MTT assay. A priori features of acute myeloid leukemia (AML) blasts relating to the apoptosis and ATG cell death pathways and their execution are characterized using microarray analysis and quantitative real-time (Q-RT) PCR. Gene and protein expression is described and quantified using Q-RT PCR and western blot analysis at specific time points after obatoclax mesylate exposure to identify pharmacodynamic biomarkers of activity and characterize the cell death mechanism in multiple-lineage leukemia (MLL)+ AML. The MTT assay is performed using obatoclax mesylate-cytotoxic chemotherapy combinations to determine synergy focusing on common cytotoxic drugs employed in AML treatment regimens.
Obatoclax mesylate efficacy is tested in a therapeutic NOG xenograft model of primary MLL+ infant AML.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01150656
|Principal Investigator:||Carolyn A. Felix, MD||Children's Hospital of Philadelphia|